Protagonist Therapeutics, Inc.Protagonist Therapeutics, Inc.Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪1.58 B‬USD
−1.47USD
‪−78.96 M‬USD
‪60.00 M‬USD
‪54.80 M‬
Beta (1Y)
1.47

About Protagonist Therapeutics, Inc.

CEO
Dinesh V. Patel
Headquarters
Newark
Employees (FY)
112
Founded
2006
ISIN
US74366E1029
FIGI
BBG002B63KM7
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PTGX is 26.58 USD — it has decreased by 1.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Protagonist Therapeutics, Inc. stocks are traded under the ticker PTGX.
Protagonist Therapeutics, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Protagonist Therapeutics, Inc. has a max estimate of 52.00 USD and a min estimate of 37.00 USD.
PTGX earnings for the last quarter are −0.58 USD whereas the estimation was −0.66 USD which accounts for 12.26% surprise. Estimated earnings for the next quarter are 0.05 USD. See more details about Protagonist Therapeutics, Inc. earnings.
Protagonist Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪60.00 M‬ USD.
Yes, you can track Protagonist Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, PTGX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Protagonist Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
PTGX reached its all-time high on Sep 7, 2021 with the price of 50.54 USD, and its all-time low was 4.47 USD and was reached on Dec 3, 2019.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 112.00 employees. See our rating of the largest employees — is Protagonist Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Protagonist Therapeutics, Inc. EBITDA is ‪−90.34 M‬ USD, and current EBITDA margin is −150.57%. See more stats in Protagonist Therapeutics, Inc. financial statements.